DNMT3A and DNMT3B have been suggested as targets of cancer therapy because enhanced DNMT3 expression can silence tumor suppressor genes in cancer cells54 and DNMT3B overexpression is reported as a poor prognostic factor in patients16. This evidence concerns the gene DNMT3B and neoplasm.